Buprenorphine Brand Names by Indication
Buprenorphine formulations are FDA-approved for two distinct indications—pain management and opioid use disorder (OUD)—with specific brand names designated for each purpose that should not be interchanged without careful consideration.
Pain Management Formulations
The following buprenorphine products are specifically approved for chronic pain treatment 1:
- Buprenex® - Injectable (IV/IM) formulation
- Butrans® - Transdermal patch system
- Belbuca® - Buccal film formulation
These pain formulations are designed for analgesic purposes and contain buprenorphine as a single agent. The transdermal patches are particularly recommended in international guidelines for patients with stable chronic pain, renal impairment, or difficulty swallowing 2. Maximum patch strengths vary by region (40-140 mcg/h depending on jurisdiction).
Opioid Use Disorder (OUD) Treatment Formulations
Buprenorphine products approved specifically for OUD treatment include 1, 3, 4:
Sublingual Formulations
- Subutex® - Sublingual tablets (buprenorphine alone, preferred for induction) 5, 6
- Suboxone® - Sublingual film (buprenorphine/naloxone combination)
- Zubsolv® - Sublingual tablets (buprenorphine/naloxone combination)
Long-Acting Injectable/Implant Formulations
- Sublocade® - Monthly subcutaneous depot injection 3, 7
- Buvidal®/Brixadi® - Weekly or monthly subcutaneous depot (available in multiple dosages) 3, 4, 7
- Probuphine® - Six-month subdermal implant 3, 4
Critical Clinical Distinctions
The buprenorphine/naloxone combination products (Suboxone®, Zubsolv®) were specifically developed to deter misuse through injection 1. The naloxone component precipitates withdrawal if injected but has minimal effect when taken sublingually as directed.
Do not switch between pain and OUD formulations without recalculating doses—the bioavailability and dosing equivalents differ substantially between routes of administration 5. For example, sublingual buprenorphine used for OUD typically ranges from 2-24 mg daily, while transdermal patches for pain use mcg/h dosing.
Special Consideration for Dual Diagnosis
For patients with both cancer pain and OUD, NCCN guidelines suggest buprenorphine may be considered first-line, with consultation from pain management or palliative care specialists recommended 2. The buprenorphine/naloxone combination may be appropriate for selected cancer pain patients 2, though this represents off-label use of OUD formulations.
When managing acute pain in patients on long-acting injectable buprenorphine for OUD (Sublocade®, Brixadi®), multimodal analgesia is essential, as the extended half-life and receptor occupancy complicate the use of full opioid agonists 8.